![]() ![]() people who have had only 1 dose have completed their primary vaccine series.moderately to severely immunocompromised people who have had both doses plus additional dose of an mRNA vaccine have completed their primary vaccine series.people who have had both doses have completed their primary vaccine series (referred to as ‘fully vaccinated’ in previous reports).people who have had only 1 dose are partially vaccinated.people who have had 3 doses have completed their primary vaccine series.people who have had only 1 or 2 doses are partially vaccinated.For 3-dose vaccine (Pfizer-BioNTech Comirnaty ages 6 months to 4 years): Booster doses are not part of the primary series. The number of doses depends on the specific vaccine product. In this report, people have ‘ completed the primary series’ (referred as ‘fully vaccinated’ in previous reports) once they’ve received all vaccine doses in the series. Vaccination status definitions Primary series Novavax Nuvaxovid for ages 18 and older.Original and Omicron BA.1 for ages 6 and older.Original and Omicron BA.4/BA.5 for ages 18 and older, and.Original and Omicron BA.1 for ages 12 and older.Original and Omicron BA.4/BA.5 for ages 5 and older, and.Pfizer-BioNTech Comirnaty for ages 5 to 11 years and 16 and older.Vaccines currently authorized for use as booster doses in Canada include: ![]() AstraZeneca Vaxzevria (ages 18 and older).Moderna Spikevax (3 formulations: ages 6 months to 5 years, ages 6 to 11 years, and ages 12 and older).Pfizer-BioNTech Comirnaty (2 formulations: ages 5 to 11 years and ages 12 and older).Pfizer-BioNTech Comirnaty (ages 6 months to 4 years).Vaccines authorized for use for primary vaccine series in Canada currently include: 3-dose vaccine Individuals who have not yet received previously recommended doses, including a primary series and fall 2022 booster, should receive them now, consistent with the Guidance on COVID-19 vaccine booster doses: Initial considerations for 2023.The booster dose should preferably be a bivalent Omicron-containing mRNA vaccine.adults 18 years of age and older who are moderately to severely immunocompromised due to an underlying condition or treatment.adult residents of long-term care homes and other congregate living settings for seniors, or those with complex medical needs.adults 65 to 79 years of age, particularly if they do not have a known history of SARS-CoV-2 infection.An additional booster dose may be offered, 6 or more months after the last COVID-19 vaccine dose or infection, to individuals who are at risk of severe illness from COVID-19, including:.Starting in the spring of 2023, NACI recommends that: On March 3, 2023, NACI released their most recent statement.Please refer to the COVID-19 vaccine chapter of the Canadian Immunization Guide for more details on: ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |